News
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
Penn engineers will develop on-demand, on-site mRNA manufacturing
With an NSF grant, Penn Engineering researchers are developing a new manufacturing technique that would be able to produce mRNA sequences in a way that removes the need for cryogenic temperatures.
Co-founder of Avisi Technologies named one of the Greater Philadelphia’s Inno Under 25
long with co-founder Brandon Kao, Rui Jing Jiang started Avisi Technologies in 2017, developing VisiPlate, a nanotechnology-enabled ocular implant to treat glaucoma.
At-home COVID-19 results with the click of a smartphone
chers have developed a highly-sensitive rapid antigen test that can detect small loads of SARS-CoV-2
Recupero Robotics launches
Dr. Johnson and a team of collaborators have launched Recupero Robotics with the help of PCI Ventures.
Webinar Recording: Latest Trends in Life Science Investing
PCI hosted a webinar on Septembe 13, 2021 focused on the latest trends in the venture capital landscape. The speaker was Barbara Schilberg, Managing Director and Chief Executive Officer of BioAdvance.
Jean Bennett, M.D., Ph.D., joins REGENXBIO Board of Directors
She will serve as a member of REGENXBIO's Nominating and Corporate Governance Committee.
Inspired by the late Tachi Yamada, Jim Wilson launches new nonprofit targeting underserved ultra-rare diseases
A group of powerhouse biotech leaders is coming together to launch a new nonprofit, one aimed at delivering therapies to rare disease populations they believe pharma is leaving behind.
BioNTech reports promising data on mRNA cocktail in mouse models of colon cancer and melanoma
A BioNTech-led team designed a cocktail of mRNAs that instruct cells to produce four cancer-fighting molecules.
Smart dental implants
Geelsu Hwang of the School of Dental Medicine and colleagues are developing a smart dental implant that resists bacterial growth and generates its own electricity through chewing and brushing to power
iECURE emerges with $50M to search for ‘holy grail’ and ‘untapped frontier’ of gene editing
The biotech will use the funds for a slate of gene insertion programs for liver disorders out of the lab of gene therapy pioneer Jim Wilson, M.D., Ph.D. at Penn.